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Background: There may be an association between the responsiveness to erythropoiesis-stimulating agent (ESA)
and the nutritional status on mortality of maintenance hemodialysis (MHD) patients. Therefore, we assessed the
associations of geriatric nutritional risk index (GNRI) and ESA resistance index (ERI) in mortality in MHD patients.
Methods: A total of 298 MHD patients were enrolled. Unadjusted and adjusted Cox regression analyses for
all-cause mortality were performed. Odds ratios were estimated using a logistic regression model for the
association between the GNRI and ERI and mortality, adjusting for potential confounders.
Results: During the follow-up period of 34.6 ± 6.1 months, 51 died with 31 cardiovascular deaths. Receiver
operating curve analyses indicated the cutoff values of GNRI and ERI for mortality were 94.9 and 13.5, respectively.
When subjects were stratified by ERI and GNRI values into four groups, those who had low GNRI and high ERI were
associated with the highest risk of mortality among the four groups (log-rank p < 0.001).
Conclusions: High ERI and low GNRI were associated with an increased risk of all-cause mortality.
Keywords: Geriatric nutritional risk index, Erythropoiesis-stimulating agent, Hyporesponsiveness, Hemodialysis,
MortalityBackground
Protein-energy wasting (PEW) is a major problem in end-
stage renal disease (ESRD) patients, and its reported preva-
lence has ranged from about 20 to 78 % [1]. Since nutri-
tional risk is one of the strongest predictors of increased
mortality in maintenance hemodialysis (MHD) patients,
and evaluation of nutritional status and nutritional manage-
ment are essential clinical procedures for managing MHD
patients [2, 3], it is necessary to regularly screen patients for
PEW by making a variety of measurement with a variety of
measures [4]. The geriatric nutritional risk index (GNRI) is* Correspondence: knitta@kc.twmu.ac.jp
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status in a number of pathological conditions that is based
on body weight, height, and serum albumin levels. Some
studies have investigated the reliability of the GNRI as a
tool for assessing malnutrition in HD patients [5] and pre-
dicting their overall mortality [6, 7].
The development of erythropoiesis-stimulating agents
(ESAs) has resulted in substantial health benefits for
ESRD patients, including improved quality of life, re-
duced need for blood transfusion, and increased exercise
capacity. Unfortunately, however, a considerable propor-
tion of ESRD patients exhibit a suboptimal hematologic
response to ESAs as evidenced by the persistence of
anemia despite adequate dosing or by the need for high
ESA doses to achieve the recommended hemoglobine is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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HD patients have been found to be associated with mor-
tality [9], and hyporesponsiveness to ESA therapy is
known to predict a poorer outcome [10]. Both high-dose
ESA therapy and low Hb levels may contribute to poorer
outcomes of HD patients who are hyporesponse to ESAs
[11, 12].
The aim of the present study was to clarify the rela-
tionship between both the GNRI and responsiveness to
ESA of MHD patients and their long-term mortality.
Methods
Study design
This was a prospective, observational cohort study con-
ducted at a single center in Japan. The subjects were re-
cruited from among patients who had been routinely
dialyzed via an arteriovenous fistula in the dialysis unit
of the Jyoban Hospital for at least 6 months. The Institu-
tional Review Board of the Jyoban Hospital approved all
study protocols (no. 11), and the protocols were carried
out in accordance with the Declaration of Helsinki
guidelines regarding ethical principles for medicalTable 1 Baseline characteristics of the study population
All patients (n = 298) ERI quartiles
Q1 (n = 74)
Age, years 66.0 ± 13.1 61.7 ± 13.0
Male, % 187 (62.8 %) 54 (73.0 %)
Diabetes, % 144 (48.3 %) 39 (52.7 %)
Cardiovascular disease, % 78 (26.2 %) 22 (29.7 %)
Dialysis vintage, years 3.3 (1.2–6.7) 2.8 (1.1–5.6)
Kt/V 1.4 ± 0.2 1.4 ± 0.2
Systolic BP, mmHg 153.1 ± 17.2 154.6 ± 17.6
Diastolic BP, mmHg 79.8 ± 11.5 82.6 ± 11.8
Pulse pleasure, mmHg 73.3 ± 13.1 72.0 ± 13.1
Body mass index, kg/m2 22.0 ± 3.5 23.0 ± 3.2
Albumin, g/dl 3.7 ± 0.3 3.7 ± 0.3
nPCR, g/kg/dl 0.8 ± 0.2 0.8 ± 0.2
CRP, mg/dl 0.8 ± 0.0 0.3 ± 0.7
Hemoglobin, g/dl 10.9 ± 1.0 11.1 ± 0.8
Total cholesterol, mg/dl 150.6 ± 30.4 150.9 ± 29.7
Calcium (corrected), mg/dl 9.1 ± 0.6 9.1 ± 0.6
Phosphorus, mg/dl 4.9 ± 1.6 5.0 ± 1.4
Intact-PTH, pg/ml 94 (54–168) 109 (67–179)
GNRI 96.3 ± 8.7 99.0 ± 8.1
Ferritin, ng/ml 63 (24–125) 56 (25–133)
TSAT, % 21.6 ± 10.3 24.7 ± 9.5
ERI, IU/kg/week/Hb 8.2 (5.0–13.1) 3.6 (2.7–4.1)
Continuous values are expressed as means ± SD. Count data are expressed as perce
Abbreviations: BP blood pressure, nPCR normalized protein catabolic rate, CRP C-reactiv
resistance indexresearch involving human subjects. Written informed
consent was obtained from every subject.
HD patients with a malignancy, active inflammation,
liver cirrhosis, gastrointestinal bleeding, cardiac valvu-
lar disease, or severe illness were excluded from par-
ticipation and were transferred to another dialysis
unit for intensive care. The patients who were en-
rolled as subjects (n = 298) underwent stable regular
HD with a bicarbonate dialysate. Their underlying
diseases of ESRD were as follows: diabetic nephropa-
thy (n = 144), chronic glomerulonephritis (n = 76), hyper-
tensive nephrosclerosis (n = 70), chronic pyelonephritis
(n = 3), and unknown (n = 5). Autosomal-dominant
polycystic kidney disease patients often have higher
Hb levels and lower ESA requirements than ESRD
patients with other underlying diseases, and they were
excluded.
All patients were on thrice-weekly HD sessions. Blood
pressure (BP) was measured with a mercury sphygmo-
manometer with the patient in the supine position after
resting for 10 to 15 min, and mean values for the 1-
month period preceding enrollment were used in theP value
Q2 (n = 75) Q3 (n = 75) Q4 (n = 74)
65.3 ± 11.8 66.8 ± 14.1 70.2 ± 12.2 0.0010
49 (65.3 %) 47 (62.7 %) 37 (50.0 %) 0.0340
38 (50.7 %) 34 (45.3 %) 33 (44.6 %) 0.7023
21 (28.0 %) 18 (24.0 %) 17 (23.0 %) 0.7555
3.5 (1.1–8.1) 3.6 (1.1–7.6) 3.5 (1.3–6.8) 0.6318
1.4 ± 0.3 1.4 ± 0.2 1.4 ± 0.3 0.5231
149.4 ± 17.6 155.5 ± 17.2 153.0 ± 16.2 0.1354
77.9 ± 11.1 80.6 ± 12.2 78.0 ± 10.4 0.0357
71.5 ± 13.2 74.9 ± 12.4 75.0 ± 13.5 0.2061
22.5 ± 3.7 21.8 ± 3.6 20.6 ± 2.9 0.0002
3.7 ± 0.3 3.6 ± 0.3 3.6 ± 0.4 0.2525
0.9 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.7969
0.3 ± 0.6 0.4 ± 0.8 0.5 ± 0.9 0.4315
11.2 ± 0.8 10.7 ± 1.0 10.4 ± 1.1 <0.0001
151.7 ± 32.9 152.2 ± 32.9 147.6 ± 25.9 0.7929
9.1 ± 0.6 9.2 ± 0.6 9.1 ± 0.5 0.2019
5.4 ± 1.7 4.4 ± 1.6 4.7 ± 1.6 0.0014
102 (47–156) 75 (49–151) 110 (46–183) 0.2870
97.6 ± 9.2 95.4 ± 8.6 93.3 ± 8.0 0.0003
65 (21–125) 44 (21–108) 72 (41–144) 0.0893
22.5 ± 10.7 21.0 ± 10.2 18.3 ± 10.0 0.0016
6.2 (5.4–7.0) 10.7 (9.3–11.7) 17.5 (14.8–20.7) <0.0001
ntages
e protein, PTH parathyroid hormone, TSAT transferrin saturation, ERI erythropoiesis
Table 2 Predictors of ERI using univariate and multivariate
regression analyses
Univariate Multivariate
β p value β p value
Age 0.140 0.0418 0.149 0.0118
Female vs male 0.260 0.0001 0.233 0.0003
Dialysis vintage 0.038 0.5373 0.032 0.5999
Diabetes −0.013 0.8169 −0.017 0.7609
Cardiovascular disease −0.021 0.7035 −0.013 0.8069
Kt/V −0.034 0.6128 −0.025 0.7009
nPCR 0.019 0.7537
Log-CRP 0.081 0.1635
Total cholesterol −0.203 0.0010 −0.194 0.0011
Diastolic BP 0.032 0.6049
Calcium (corrected) −0.044 0.4237
Phosphorus −0.117 0.0391 −0.105 0.0575
Intact-PTH 0.019 0.7430
Ferritin 0.010 0.8635
TSAT −0.182 0.0023 −0.193 0.0004
GNRI −0.203 0.0007 −0.205 0.0004
Multivariate analysis adjusted for the value for age, gender, dialysis vintage,
presence of diabetes and cardiovascular disease, Kt/V, serum levels of total
cholesterol and phosphorus, TSAT, and GNRI
Abbreviations: nPCR normalized protein catabolic rate, BP blood pressure,
CRP C-reactive protein, PTH parathyroid hormone, TAST transferrin saturation,
GNRI geriatric nutritional risk index
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normotensive edema-free state. History of previous
cardiovascular disease was collected from the medical
records. Diabetes was recorded as a history or pres-
ence of diabetes and/or a fasting plasma glucose con-
centration >126 mg/dl or HbA1c concentration >6.5 % or
prescription of glucose-lowering agents.
The study period was divided into two phases to
evaluate the time-dependent risk of mortality based on
subjects’ longitudinal dialysis status. The first phase
(12 months) was used to collect laboratory data to evalu-
ate longitudinal dialysis status. The second phase (the
subsequent 2 years) was used as a means of evaluating
the time-dependent risk of mortality. In order to use
longitudinal dialysis condition as a predictive value, la-
boratory data were not assessed during the second
phase. The ESA resistance index (ERI) was calculated by
dividing the weekly weight-adjusted ESA dose (IU/kg/
week) by the Hb concentration (g/dL), as previously
described [12]. Patients were divided into four groups
by quartiles (Q) of ERI as follows: Q1 ERI <4.96, Q2
ERI =4.97–8.30, Q3 ERI =8.31–13.1, and Q4 >13.2 IU/kg/
week/g/L.
Laboratory and nutrition parameters
Blood sampling after an overnight fast was performed
before the mid-week dialysis session day. Serum urea ni-
trogen, creatinine, calcium, phosphorous, albumin, total
cholesterol, ferritin, transferrin saturation, and C-
reactive protein (CRP) levels and the Hb concentration
were measured by standard laboratory methods. Total
calcium values were corrected by the patient’s albumin
level. Intact parathyroid hormone (iPTH) was measured
by an immunoradiometric assay. Body mass index (BMI)
was expressed in kilograms per square meter. Body
weight was calculated as dry weight defined as the post-
dialysis weight of normotensive patients with no signs of
overhydration. Urea kinetics were assessed by measuring
a blood-based dialysis parameter, Kt/V [13], and the
mean value of the three measurements during each of
the 3 months before the start of the study was used in
the analysis. The normalized protein catabolism rate
(nPCR) was used as an indirect indicator of protein in-
take and was calculated by using the formula previously
described [14].
The GNRI was calculated by modifying the nutritional
risk index for elderly patients reported by Yamada et al. [5]
as follows: GNRI =[14.89 × albumin (g/dl)] + [41.7 × (body
weight/ideal body weight)]. We used the body weight
value at the end of the dialysis session to calculate
the BMI. When a body weight exceeded the ideal
body weight, body weight/ideal body weight was set
equal to 1 [6]. The ideal body weight in the present
study was calculated using height and a BMI of 22,which has been reported to be associated with the low-
est morbidity rate in the Asian population [15].
Anemia treatment strategy
Subjects’ anemia was treated according to the guidelines
published in 2004 by the Japanese Society of Dialysis
Therapy (JSDT) [16]. The target Hb level was 10–11 g/dL,
and epoetin beta was administered to achieve the tar-
get Hb level. Intravenous iron was administered
whenever a subject’s transferrin saturation was found
to be <20 % or the serum ferritin level was found to
be <100 ng/mL.
Study outcome
Data for endpoints were obtained from hospital charts
and by telephone interviews of patients that were
conducted by trained interviewers who were blinded
to the study protocol. The primary endpoint of the
study was all-cause mortality during the follow-up
period from 1 July 2011 to 31 July 2014. The second-
ary endpoint was cardiovascular death, including
death due to heart failure, myocardial infarction,
arrhythmia, and stroke. The vital status of the sub-
jects was assessed by searching their electronic dialy-
sis records. Patients were censored if they were alive
on 31 July 2014.
Fig. 1 Scatter diagram showing the association between the GNRI and ERI
Table 3 Likelihood of the worst ESA hyporesponsiveness using
multivariate logistic regression analyses to compare the highest
versus lowest quartiles of ERI
Odds ratio 95 % CI p value
Age 1.029 1.004–1.057 0.0242
Female vs male 2.385 1.193–4.868 0.0138
Dialysis vintage 1.012 0.962–1.064 0.6325
Diabetes 0.925 0.501–1.708 0.8027
Cardiovascular disease 0.872 0.436–1.688 0.6891
Kt/V 0.631 0.148–2.586 0.5227
GNRI (for 1 SD↑) 0.681 0.494–0.930 0.0155
Total cholesterol (for 1 SD↑) 0.643 0.456–0.892 0.0077
Phosphorus (for 1 SD↑) 0.882 0.648–1.191 0.4133
TSAT (for 1 SD↑) 0.582 0.415–0.797 0.0006
GNRI geriatric nutritional index, TSAT transferrin saturation
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Normally distributed, unpaired continuous values were
expressed as means ± SD and compared by performing
an analysis of variance. Nonparametric values were
expressed as median values and compared by perform-
ing the Kruskal-Wallis test. Categorical values were
expressed as percentages and compared by performing
the Fisher’s exact test. Logistic regression analysis was
used in a model to determine how independent variables
predicted the ERI value. We used Spearman’s rank-order
correlation coefficients for selected analyses where indi-
cated. Multivariate regression analyses including linear
and logistic regression were performed to analyze the
data for associations between clinical parameters and
ERI. Our fully adjusted model was adjusted for age, gen-
der, dialysis vintage, presence of diabetes, history of car-
diovascular disease, Kt/V (single pool), serum total
cholesterol and phosphorus levels, transferrin saturation
(TSAT), and GNRI.
The survival analysis was based on the Kaplan-Meier
curve with subjects censored for death. A log-rank test
was used to compare the survival rates of the two
groups. Receiver operating characteristic (ROC) analysis
was used to select cutoff values of GNRI and ERI for all-
cause mortality. We considered some variables that pos-
sess P value <0.10 in univariate logistic regression ana-
lysis as independent variables for multivariate analyses.
A multivariate logistic regression model with adjustment
for multiple factors was used to evaluate mortality risk.
Results were expressed as odds ratio (OR) and 95 % con-
fidence interval (CI). A p value of <0.05 was considered
statistically significant. All statistical analyses were per-
formed by using the SAS version 9.2 software program
(SAS Institute Inc., Cary, NC, USA) for Windows per-
sonal computers.
Results
Table 1 shows the baseline characteristics of the 298 HD
patients according to their ERI quartiles. The mean agewas 66.0 ± 13.1 years, 62.8 % were males, 48.3 % were
diabetic, and mean dialysis vintage was 5.4 ± 6.2 years.
Patients with higher ERI were older and had lower
GNRI, BMI, Hb, phosphorus, and TSAT. There was a
significant relationship between ERI quartiles and both
BMI (p = 0.0002) and GNRI (p = 0.0003).
Table 2 shows the results of the multivariate linear
regression analyses between ESA responsiveness and
clinical parameters after adjustment for significant
confounders by univariate analyses (p < 0.05). Both
older age (β = 0.149) and female gender (β = 0.233)
were significant and independent predictors of ERI
using multivariate regression analyses. In addition,
serum total cholesterol (β = −0.194), TSAT (β = −0.193),
and GNRI (β = −0.205) were found to be independent
negative predictors of ERI. As shown in Fig. 1, the
ERI was inversely correlated with the GNRI (r = 0.287,
p < 0.0001).
Table 3 shows the likelihood of ESA at the worst hy-
poresponsiveness using multivariate logistic regression
Fig. 2 Receiver operating characteristic analysis showing cutoff values of GNRI and ERI for increased all-cause mortality
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lower quartiles (as reference) of responsiveness to ESA.
The likelihood of belonging to the highest ERI quartile
in comparison with the three lower quartiles decreased
for every 1 SD higher GNRI (OR = 0.681; 95 % CI =
0.494 –0.930), every 1 SD higher total cholesterol (OR =
0.643; 95 % CI = 0.456–0.892), and every 1 SD higher
TSAT (OR = 0.582; 95 % CI = 0.415–0.797).
The mean follow-up period was 34.6 ± 6.1 months. Of
the 298 enrolled subjects, 51 died during the follow-up
period, and the causes of death were cardiovascular dis-
ease in 31 subjects (60.7 %) and non-cardiovascular dis-
eases including infection and malignancy in 20 subjects
(39.3 %).
ROC analyses were performed to select the optimal
cutoff values of GNRI and ERI for increased risk of
mortality. Figure 2 shows that the cutoff value of
GNRI was 94.9 (area under curve = 0.664, p = 0.0001)
and that of ERI was 13.5 (area under curve = 0.574,Fig. 3 Kaplan-Meier curve of survival probability according to the GNRI and
(GHEL) (n = 142); low GNRI and high ERI (GLEH) (n = 36); and low GNRI andp = 0.1022). When the subjects were stratified accord-
ing to their ERI and GNRI values into four groups,
those who had low GNRI and high ERI were associ-
ated with the highest risk of mortality among the four
groups (Fig. 3; log-rank p < 0.001).
In an attempt to clarify whether the combination of
ERI and poor nutritional status could be a better pre-
dictor for all-cause mortality of MHD patients, we ex-
amined ORs of the combination factor (four groups
stratified by ERI and GNRI) by multivariate analyses and
compared the OR of GNRI only. As shown in Table 4,
GNRI was an independent predictor of all-cause mortal-
ity (OR = 0.929; 95 % CI = 0.894–0.964; p < 0.001). In
addition, low GNRI and high ERI (GLEH) was the worst
predictor of all-cause mortality (OR = 5.325; 95 % CI =
1.888–15.512; p = 0.0016).
Finally, we performed multivariate analyses of all-
cause mortality using confounders including quartiles
of ERI and GNRI. As shown in Table 5, Q1 and Q2ERI. High GNRI and ERI high (GHEH) (n = 32); high GNRI and low ERI
low ERI (GLEL) (n = 88)
Table 4 Multivariate logistic regression analysis of all-cause
mortality according to GNRI and combination factor
(four groups stratified by ERI and GVRI)
Multivariate Odds ratio 95 % CI p value
Age 1.052 1.016–1.092 0.0039
Male vs female 2.142 1.014–4.771 0.0459
Diabetes 2.013 1.017–4.078 0.0446
Diastolic BP 0.999 0.966–1.034 0.9747
nPCR 0.944 0.140–6.228 0.9521
Ferritin 1.001 0.998–1.004 0.5643
GNRI 0.929 0.894–0.964 <0.0001
GHEL 1.000
GHEH 3.234 1.036–9.701 0.0436
GLEL 3.166 1.363–7.722 0.0072
GLEH 5.325 1.888–15.512 0.0016
GHEH high GNRI and ERI high (n = 32), GHEL high GNRI and low ERI (n = 142),
GLEH low GNRI and high ERI (n = 36), GLEL low GNRI and low ERI (n = 88)
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tality, whereas Q3 of ERI only was an independent
factor for mortality.
Discussion
The results of this study showed that ESA responsive-
ness and nutritional status were associated with in-
creased risk of death after adjustment for potential
confounding factors, and, in particular, they showed that
patients with high ERI and low GNRI had the highest
risk of mortality. These findings suggest that ESA re-
sponsiveness and nutritional status should be considered
simultaneously when evaluating the relationship betweenTable 5 Multivariate logistic regression analysis of all-cause mortality
ERI
Odds ratio 95 % CI p
Age 1.052 1.016–1.092 0.0
Male vs female 2.142 1.014–4.771 0.0
Diabetes 2.013 1.017–4.078 0.0
Diastolic BP 0.999 0.966–1.034 0.9
nPCR 0.944 0.140–6.228 0.9
Ferritin 1.001 0.998–1.004 0.5
ERI Q1 2.165 0.809–6.125 0.1
ERI Q2 1.000
ERI Q3 1.326 0.477–3.809 0.5
ERI Q4 2.633 1.041–7.162 0.0
GNRI Q4
GNRI Q3
GNRI Q2
GNRI Q1renal anemia and malnutrition and mortality risk in
MHD patients.
ESA responsiveness is relative, not absolute, and the
two determinants of responsiveness are ESA dose and
Hb level. Previous studies have demonstrated associa-
tions between ESA resistance and high all-cause mortal-
ity and high cardiovascular mortality in ESRD patients
[17–19]. ERI is considered a useful means of ESA resist-
ance, but the follow-up periods in the previous studies
were relatively short (i.e., 1 or 2 years). The results of
this study showed that a combination of high ERI and
low GNRI was associated with increased mortality risk
during a mean follow-up period of 34.6 ± 6.1 months.
Because the ERI and GNRI were calculated from the
baseline data, the ERI and GNRI may have changed dur-
ing the long-term follow-up period.
ESA responsiveness varies widely according to a num-
ber of clinical factors. The results of the multivariate lo-
gistic regression analysis showed that the likelihood of
belonging to the highest ERI quartile in comparison with
the three lower quartiles decreased for every 1 SD higher
GNRI (OR = 0.681; 95 % CI = 0.494–0.930), every 1 SD
higher total cholesterol (OR = 0.643; 95 % CI = 0.456–
0.892), and every 1 SD higher TSAT (OR = 0.582; 95 %
CI = 0.415–0.797). These results suggest that nutritional
markers are independent predictors of the ESA respon-
siveness of MHD patients.
Assessment and monitoring of protein and energy nu-
tritional status are essential to prevent, diagnose, and
treat uremic malnutrition in dialysis patients [20]. Many
nutritional screening tools have been developed for use
in the elderly, children, hospitalized patients, patients in
the community, and patients with cancer or infections,according to quartiles of ERI or GNRI
GNRI
value Odds ratio 95 % CI p value
039 1.060 1.024–1.100 0.0007
459 2.067 1.019–4.382 0.0441
446 2.032 1.034–4.084 0.0395
747 1.004 0.971–1.038 0.8061
521 0.850 0.125–5.561 0.8659
643 1.001 0.998–1.005 0.4372
248
887
407
1.000
2.505 0.787–9.636 0.1235
3.305 1.066–12.547 0.0379
3.492 1.132–13.255 0.0287
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MHD patients as well [21]. The GNRI was one of the
parameters that was a predictor of increased overall
mortality in the present study. The GNRI is calcu-
lated from only a few objective components, including
serum albumin and BMI, and is a simple nutritional
screening tool [5]. Kobayashi et al. [6] reported find-
ing that HD patients whose GNRI was <90 had a
poorer nutritional status in terms of lower serum
levels of albumin and creatinine than HD patients
whose GNRI was >90. However, it is very difficult to
determine the ideal cutoff value. Park et al. [7] found
that GNRI may be a significant predictor of increased
mortality in Korean HD patients. More recently, Pani-
chi et al. [22] obtained results closer to those ob-
tained by Yamada et al. and indicated that values
below 92 may be a strong indicator of an unfavorable
outcome.
Various mechanisms, including derangements in
muscle, gastrointestinal, hematopoietic and immune sys-
tems, and abnormal activation of the inflammatory
process may explain the link between PEW and mortal-
ity in renal failure [23]. Low serum albumin and choles-
terol levels are indicators of PEW but may not be
causally responsible for negative outcome. The reduction
in muscle mass, namely sarcopenia, observed in PEW
may be due to uremic toxins or procatabolic conditions
(metabolic, hormonal, or neuropathic abnormalities).
Muscle wasting may in turn lead to reduced skeletal, re-
spiratory, and cardiac muscle function and cause func-
tional insufficiency [24].
The present study had several limitations. First, base-
line data were used to define exposure categories in this
cohort, and we were unable to examine the effect of
changes from the baseline category during the follow-up
period. Second, since this was a single center cohort
study, the data and results may not be representative of
MHD patients in other countries, particularly since the
ERI and GNRI are not widely used in Japan. Third, the
cohort size was small and the mortality rate was low.
However, the follow-up period of our cohort was longer
than in previous studies.Conclusions
A combination of a high ERI and low GNRI was an in-
dependent predictor of increased all-cause mortality in
MHD patients. In future studies, greater attention
should be focused on background factors that increase
responsiveness to ESA in addition to efforts to improve
nutritional status.Competing interest
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